

GLAXOSMITHKLINE PLC
Form 6-K
February 20, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 20 February 2018

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')
 Shares sold to meet tax liabilities

Following the vesting of awards granted in 2015 under the GlaxoSmithKline 2009 Performance Share Plan on 15 February 2018 and as notified on 16 February 2018, the notifications that follow reflect changes in the interests of Persons Discharging Managerial Responsibilities ('PDMRs') in Ordinary Shares and in American Depositary Shares ('ADSs') of the Company arising from the sale of Ordinary Shares or ADSs to meet tax liabilities.

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms E Walmsley
 - b) Position/status Chief Executive Officer
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882

a) Description of the financial instrument

b) Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.

c) Price(s) and volume(s)	Price(s)	Volume(s)
	£13.0726	65,247
d) Aggregated information	n/a (single transaction)	
d) Aggregated volume Price		
e) Date of the transaction	2018-02-16	
f) Place of the transaction	London Stock Exchange (XLON)	

1. Details of PDMR/person closely associated with them ('PCA')

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name Mr R G Connor
 b) Position/status President, Global Manufacturing and Supply
 c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882

- a) Description of the financial instrument

- b) Nature of the transaction
- The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.

- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|-----------|
| £13.0726 | 33,446 |
- d) Aggregated information
 Aggregated volume Price n/a (single transaction)
- e) Date of the transaction 2018-02-16
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr N Hirons
 b) Position/status SVP, Global Ethics & Compliance
 c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

Ordinary shares of 25 pence
each ('Ordinary Shares')
ISIN: GB0009252882

a) Description of the financial instrument

b) Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.

c) Price(s) and volume(s)

Price(s)	Volume(s)
£13.0726	16,216
n/a (single transaction)	

d) Aggregated information
Aggregated volume Price

e) Date of the transaction 2018-02-16
f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr B McNamara
b) Position/status CEO, Consumer Healthcare
c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument GlaxoSmithKline plc
American Depositary Shares ('ADSs')
ISIN: US37733W1053

b) Nature of the transaction	The sale of ADSs to meet tax liabilities further to the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.	
c) Price(s) and volume(s)	Price(s) \$37.4803	Volume(s) 14,389
d) Aggregated information Aggregated volume Price	n/a (single transaction)	
e) Date of the transaction	2018-02-16	
f) Place of the transaction	New York Stock Exchange (XNYS)	

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr D S Redfern
 - b) Position/status Chief Strategy Officer
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

a) Description of the financial instrument

b) Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.	
c) Price(s) and volume(s)	Price(s) £13.0726	Volume(s) 26,605

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- d) Aggregated information n/a (single transaction)
- e) Date of the transaction 2018-02-16
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms C Thomas
- b) Position/status SVP, Human Resources
- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

a) Description of the financial instrument

- b) Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.

- c) Price(s) and volume(s)
Price(s) Volume(s)
£13.0726 35,473

- d) Aggregated information n/a (single transaction)
- e) Date of the transaction 2018-02-16
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr P C Thomson
- b) Position/status SVP, Communications & Government Affairs
- c) Initial notification/ Initial notification

amendment

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - Ordinary shares of 25 pence each ('Ordinary Shares')
 - ISIN: GB0009252882

a) Description of the financial instrument

- b) Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.

- c) Price(s) and volume(s)

Price(s)	Volume(s)
£13.0726	20,524
- d) Aggregated information

Aggregated volume Price n/a (single transaction)
- e) Date of the transaction

2018-02-16
- f) Place of the transaction

London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr D E Troy
- b) Position/status SVP & General Counsel
- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
- Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument

GlaxoSmithKline plc
American Depositary Shares ('ADSs')
ISIN: US37733W1053

b) Nature of the transaction The sale of ADSs to meet tax liabilities further to the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.

c) Price(s) and volume(s) Price(s) Volume(s)
 \$37.4803 31,635
 n/a (single transaction)

d) Aggregated information
 Aggregated volume Price

e) Date of the transaction 2018-02-16

f) Place of the transaction New York Stock Exchange (XNYS)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Dr P J T Vallance

b) Position/status President, R&D

c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882

a) Description of the financial instrument

b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2015 under the Company's

2009 Performance Share Plan.

c) Price(s) and volume(s)	Price(s)	Volume(s)
	£13.0726	73,783
d) Aggregated information	n/a (single transaction)	
d) Aggregated volume Price		
e) Date of the transaction	2018-02-16	
f) Place of the transaction	London Stock Exchange (XLON)	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mrs V A Whyte
b) Position/status	Company Secretary
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

a) Description of the financial instrument

b) Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.
------------------------------	--

c) Price(s) and volume(s)	Price(s)	Volume(s)
	£13.0726	4,544
d) Aggregated information	n/a (single transaction)	
d) Aggregated volume Price		
e) Date of the transaction	2018-02-16	
f) Place of the transaction	London Stock Exchange (XLON)	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: February 20, 2018

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc